Understanding Tysabri and PML: What the Medical Record Shows

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Guidance

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Decades of pharmacovigilance and post-marketing studies have established a clear link between Tysabri and PML, particularly with longer treatment duration and certain risk factors. This page provides a neutral, evidence-based overview of PML symptoms, diagnosis, and the key medical records that document patient history and monitoring.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri treatment, understanding the medical evidence and legal timelines is critical. PML is an infection of the brain's white matter that typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors have been identified: the presence of anti-JC virus antibodies in the blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information emphasizes that these factors should be weighed against the expected benefit when initiating or continuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation, Diagnosis, and Mechanistic Pathways

PML symptoms can be subtle at first, including progressive weakness on one side of the body, clumsiness, visual changes, and cognitive decline. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequent reports of fatigue, gait disturbance, balance disorder, memory impairment, cognitive disorder, and muscular weakness (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with multiple sclerosis relapses, making diagnosis challenging. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. The mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on immune cells, preventing their migration from the bloodstream into the brain. This reduces inflammation in multiple sclerosis but also impairs normal immune surveillance against the JC virus. In the absence of adequate T-cell monitoring, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML.

Adequacy of Warnings and Legal Considerations in Florida

The FDA has required a boxed warning for Tysabri since its reintroduction to the market in 2006. The warning clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to monitor for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and physicians were adequately informed about the magnitude of risk, particularly for those with anti-JCV antibodies or prolonged therapy. For patients in Florida who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Florida, the statute of limitations for personal injury actions is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given that PML can have a delayed onset and progressive course, the timeline between Tysabri exposure and documented harm is critical. Patients who received Tysabri for two years or longer are at higher risk, and symptoms may not appear until months after the last infusion. The statute of limitations clock typically starts when the patient knew or should have known that Tysabri caused the PML. Consulting with an attorney experienced in pharmaceutical litigation is essential to preserve legal rights.

Timeline Between Exposure and Documented Harm

The risk of PML increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur at any time during therapy. The FAERS data show that adverse events such as multiple sclerosis relapse, gait disturbance, and cognitive disorder are frequently reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI), which may delay recognition of PML. Once PML is diagnosed, the prognosis is poor, with most patients experiencing severe disability or death. The time from symptom onset to diagnosis can vary from weeks to months, and the statute of limitations may begin at the point of diagnosis or when the link to Tysabri is reasonably suspected.

Conclusion

Tysabri-associated PML is a devastating condition with well-defined risk factors and a clear mechanistic basis. The FDA has mandated strong warnings, but affected patients in Florida must be aware of the legal deadlines for pursuing claims. Given the complexity of both the medical and legal issues, individuals who have developed PML after Tysabri treatment should seek prompt evaluation by a neurologist and consultation with a qualified attorney to assess their options within the applicable statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury actions is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given the delayed onset of PML, it is crucial to consult an attorney promptly to preserve your rights.

What are the primary risk factors for developing PML while on Tysabri?

The three primary risk factors are: the presence of anti-JC virus antibodies in the blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients taking Tysabri?

Diagnosis typically involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. Symptoms can be subtle and overlap with multiple sclerosis relapses, so healthcare professionals are instructed to monitor for any new signs and withhold Tysabri immediately if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.